CTI BioPharma

CTI was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. We strive to do business better than other biopharmaceutical companies. Better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. A willingness to push the limits to achieve challenging goals is the essential attribute that sets CTI employees apart.
Seattle, US
Size (employees)
100 (est)-32%
CTI BioPharma was founded in 1992 and is headquartered in Seattle, US

CTI BioPharma Office Locations

CTI BioPharma has an office in Seattle
Seattle, US (HQ)
600 3101 Western Ave

CTI BioPharma Data and Metrics

CTI BioPharma Financial Metrics

CTI BioPharma's revenue was reported to be $57.4 m in FY, 2016 which is a 256% increase from the previous period.

Revenue (FY, 2016)

57.4 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

56 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(53 m)

EBIT (FY, 2016)

(49.2 m)

Market capitalization (21-Jul-2017)

98.9 m

Cash (31-Dec-2016)

44 m


62.8 m
CTI BioPharma's current market capitalization is $98.9 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


34.7 m60.1 m16.1 m57.4 m

Revenue growth, %


Cost of goods sold

137 k895 k1.9 m1.4 m

Gross profit

34.5 m59.2 m14.2 m56 m

Gross profit Margin, %


R&D expense

65 m

General and administrative expense

45.3 m

Operating expense total

76.1 m146.3 m130.8 m106.6 m


(41.5 m)(86.2 m)(116.7 m)(49.2 m)

EBIT margin, %


Interest expense

1 m1.9 m2.1 m2.6 m

Net Income

(43.6 m)(94.2 m)(120.8 m)(53 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


71.6 m70.9 m128.2 m44 m

Accounts Receivable

235 k2 m282 k378 k


3.6 m3.4 m3.7 m1.5 m

Current Assets

80.5 m80.5 m135 m55.8 m


5.5 m4.6 m3.7 m3 m

Total Assets

93.7 m92.3 m144.3 m63.8 m

Accounts Payable

5.1 m6.4 m10.6 m7.2 m

Total Debt

13.3 m17.4 m56.5 m7.9 m

Current Liabilities

20.1 m36.3 m72.4 m40.6 m

Total Liabilities

56.1 m

Retained Earnings

(1.9 b)(2 b)(2.1 b)(2.2 b)

Total Equity

42.8 m38.5 m47.4 m7.8 m

Debt to Equity Ratio

0.3 x0.5 x1.2 x1 x

Debt to Assets Ratio

0.1 x0.2 x0.4 x0.1 x

Financial Leverage

2.2 x2.4 x3 x8.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(43.6 m)(94.2 m)(120.8 m)(53 m)

Depreciation and Amortization

1.6 m1.1 m990 k831 k

Accounts Receivable

(227 k)(2 m)1.6 m(156 k)


4.5 m46 k(402 k)567 k

Accounts Payable

(5.8 m)1.5 m4.4 m(3 m)

Cash From Operating Activities

(35.8 m)(39.6 m)(95.2 m)(76.7 m)

Purchases of PP&E

(1.7 m)(333 k)(78 k)(137 k)

Cash From Investing Activities

(1.5 m)(541 k)(78 k)(137 k)

Cash From Financing Activities

59 m36 m152 m(7.4 m)

Interest Paid

933 k1.9 m2.1 m4.4 m
Y, 2016


-1.3 x


-0.8 x


1 x


0.1 x

Financial Leverage

8.2 x

CTI BioPharma Operating Metrics

FY, 2016

Phase III Trials


CTI BioPharma Market Value History

CTI BioPharma Online and Social Media Presence

CTI BioPharma Company Life and Culture

You may also be interested in